Li DG, et al. - Researchers analyzed retrospectively the cost of the 597 topical dermatologic generic drugs to evaluate the correlation of changes in drug price and the number of US Food and Drug Administration (FDA)-approved manufacturers. They identified the number of manufacturers and the price per unit from the FDA Orange Book and the National Average Drug Acquisition Cost (NADAC) database, respectively, for 2013 through 2016. They observed a negative association between drug price change and the median number of manufacturers indicating a healthy market competition in controlling the costs of generic drug prices within dermatology.